Yida Li

Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated <scp>EGFR</scp>‐mutant nonsmall cell lung cancer with brain metastasis

Yang Zhao, Shuyan Li, Xi Yang et al. · International Journal of Cancer · 2021 · 61 citations

Medicine, Pharmacology, Brain Metastasis +13

Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy

Tiantian Guo, Jianjiao Ni, Xi Yang et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 50 citations

Radiation Therapy, Medicine, Recurrence Analysis +5

Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer With Brain Metastases

Fan Yu, Jianjiao Ni, Wanqin Zeng et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 50 citations

Neuro-oncology, Radiation Medicine, Radiation Therapy +9

Three-field <i>versus</i> two-field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short-term outcomes of a randomized clinical trial

B Li, Hong Hu, Yunkui Zhang et al. · British journal of surgery · 2020 · 38 citations · Full text

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors

Yue Zhou, Bo Wang, Jinghan Qu et al. · Lung Cancer · 2020 · 29 citations

Neuro-oncology, Survival Outcomes, Medicine +7